Effect of Curcumin on Liver Damage Caused by Cisplatin in Rats

Abstract

The toxic effects that occur in many patients receiving chemotherapy seriously affect the liver. Cisplatin used in many types of cancer causes hepatotoxicity by increasing oxidative stress in the liver. Curcumin is a compound with antioxidant, antifibrogenic and anticarcinogenic features. Due to these healing effects of curcumin, it is recommended in many areas as an antioxidant. In this study, the effect of the antioxidant properties of curcumin on the liver of rats given cisplatin was investigated. For this purpose, 26 adult male Wistar Albino rats were divided into 4 groups. Control group rats were given DMSO for 6 days. Curcumin group rats were given intraperitoneally 200mg/kg curcumin for 6 days. In the Cisplatin + Curcumin group, 200 mg/kg curcumin intraperitoneally was given daily for 6 days and a single dose of 20 mg/kg cisplatin intraperitoneally was given on the 3rd day only. On the 7th day, after the animals were sacrificed, liver tissue was taken for light and electron microscopy analysis. As a result, it showed that cisplatin causes steatosis in hepatocytes, congestion in sinusoids and portal areas even when administered acutely. Cisplatin is thought to cause these effects by increasing oxidative stress in the liver. Curcumin was observed to be alleviating hepatotoxic effects cisplatin which was revealed by both light and electron microscopic findings. 

Keywords

• cisplatin
• curcumin
• hepatotoxicity

References

1. 1. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Experimental and Toxicologic Pathology. 2009;61(3):223-42.
2. 2. Murray D, Mirzayans R. Cellular Responses to Platinum-Based Anticancer Drugs and UVC: Role of p53 and Implications for Cancer Therapy. Int J Mol Sci. 2020;21(16).
3. 3. Zheng X-N, Wang X-W, Li L-Y, Xu Z-W, Huang H-Y, Zhao J-S, et al. Pu-erh tea powder preventive effects on cisplatin-induced liver oxidative damage in Wistar rats. Asian Pac J Cancer Prev. 2014;15(17):7389-94.
4. 4. Yu D, Gu J, Chen Y, Kang W, Wang X, Wu H. Current Strategies to Combat Cisplatin-Induced Ototoxicity. Frontiers in pharmacology. 2020;11:999.
5. 5. Tsang RY, Al-Fayea T, Au H-J. Cisplatin overdose. Drug safety. 2009;32(12):1109-22.
6. 6. Naqshbandi A, Khan W, Rizwan S, Khan F. Studies on the protective effect of flaxseed oil on cisplatin-induced hepatotoxicity. Human & experimental toxicology. 2012;31(4):364-75.
7. 7. Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacological Research. 2008;57(2):125-31.
8. 8. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer research. 2003;23(1/A):363-98.

9. 9. Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, et al. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Frontiers in pharmacology. 2020;11:01021.
10. 10. Pandey A, Gupta R, Srivastava R. Curcumin-the yellow magic. Asian J Appl Sci. 2011;4(4):343-54.
11. 11. Rivera‐Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver International. 2009;29(10):1457-66.
12. 12. Farzaei MH, Zobeiri M, Parvizi F, El-Senduny FF, Marmouzi I, Coy-Barrera E, et al. Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective. Nutrients. 2018;10(7).
13. 13. Ingawale DK, Mandlik SK, Naik SR. Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism (s): a critical discussion. Environmental toxicology and pharmacology. 2014;37(1):118-33.
14. 14. Auger C, Alhasawi A, Contavadoo M, Appanna VD. Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders. Frontiers in cell and developmental biology. 2015;3:40.
15. 15. Casas-Grajales S, Muriel P. Antioxidants in liver health. World journal of gastrointestinal pharmacology and therapeutics. 2015;6(3):59.
16. 16. Waseem M, Bhardwaj M, Tabassum H, Raisuddin S, Parvez S. Cisplatin hepatotoxicity mediated by mitochondrial stress. Drug and chemical toxicology. 2015;38(4):452-9.
17. 17. Muriel P. Cytokines in liver diseases. Wiley Online Library; 2007.
18. 18. Martins N, Santos N, Curti C, Bianchi M, Santos A. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. Journal of Applied Toxicology: An International Journal. 2008;28(3):337-44.
19. 19. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Overview on the mechanisms of drug-induced liver cell death. Annals of Hepatology. 2002;1(4):162-8.
20. 20. Palipoch S, Punsawad C, Koomhin P, Suwannalert P. Hepatoprotective effect of curcumin and alpha-tocopherol against cisplatin-induced oxidative stress. BMC complementary and alternative medicine. 2014;14(1):111.
21. 21. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clinical and experimental pharmacology and physiology. 2012;39(3):283-99.
22. 22. Vera‐Ramirez L, Pérez‐Lopez P, Varela‐Lopez A, Ramirez‐Tortosa M, Battino M, Quiles JL. Curcumin and liver disease. Biofactors. 2013;39(1):88-100.
23. 23. Ak T, Gülçin İ. Antioxidant and radical scavenging properties of curcumin. Chemico-biological interactions. 2008;174(1):27-37.
24. 24. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). The Journal of Alternative & Complementary Medicine. 2003;9(1):161-8.
25. 25. Ghosh N, Ghosh R, Mandal V, Mandal SC. Recent advances in herbal medicine for treatment of liver diseases. Pharmaceutical biology. 2011;49(9):970-88.
26. 26. Wang Y, Hu P-C, Gao F-F, Lv J-W, Xu S, Kuang C-C, et al. The protective effect of curcumin on hepatotoxicity and ultrastructural damage induced by cisplatin. Ultrastructural pathology. 2014;38(5):358-62.